About Eli Lilly
Funding & Growth
✓ Pros
- • Exceptional stock performance and growth
- • Strong diabetes and obesity pipeline (Mounjaro)
- • Heavy R&D investment
- • Good work-life balance
- • Excellent benefits
✗ Cons
- • Large company processes
- • Competitive diabetes market
- • Manufacturing challenges with GLP-1 demand
🏢 Working Here
Eli Lilly operates computational biology across Boston, MA (major hub for discovery research and genetics), Indianapolis, IN (global headquarters), San Diego, CA, and New York, NY.
The Boston presence reflects Lilly's strategic focus on proximity to cutting-edge computational biology talent in Kendall Square, with access to MIT, Harvard, Broad Institute, and the broader biotech ecosystem.
Lilly leads in diabetes/obesity (Mounjaro/Zepbound GLP-1 therapies), Alzheimer's (donanemab), oncology (KRASG12C inhibitors), and immunology.
Bioinformaticians work across the pipeline from human genetics target discovery to Phase III clinical biomarkers.
Indianapolis headquarters offers exceptional cost of living and Midwestern work-life balance, while Boston provides cutting-edge science access.
The company has made major AI/ML investments including Atomwise partnership and internal platform development.
Work involves analyzing large-scale clinical trial data, genetics for target validation, digital health data integration, and multi-omic patient profiling.
Each location has strengths: Boston for discovery and genetics, Indianapolis for clinical development and patient proximity.
🧬 Bioinformatics Focus
Lilly's computational biology spans metabolic diseases, neurodegeneration, and oncology. Key areas:
- Diabetes and obesity - analyzing clinical trial data from Mounjaro and Zepbound, understanding GLP-1/GIP biology through multi-omic approaches, predicting cardiovascular benefits, patient stratification for weight loss response,
- Alzheimer's disease - analyzing biomarkers from donanemab trials (amyloid PET, tau, cognitive measures), understanding disease progression, identifying early intervention opportunities,
- Cancer genomics - KRASG12C inhibitor biomarkers, developing combination therapy strategies, understanding resistance mechanisms,
- Immunology - analyzing RA, psoriasis, atopic dermatitis patient samples, JAK inhibitor optimization,
- AI/ML for drug discovery - using deep learning for compound design, predicting drug-target interactions, optimizing molecules for developability. Lilly has pioneered clinical trial innovation including adaptive designs informed by computational modeling. The company maintains large longitudinal patient datasets and integrates real-world evidence. Technical challenges include analyzing complex phenotypes like cognition, integrating imaging data (PET scans, MRI) with molecular data, and developing predictive models that inform clinical decisions.
📈 Career Growth & Development
Career Paths
Scientist Track
Management Track
Compensation
Competitive base salaries, 15-20% bonuses, stock grants, and industry-leading benefits including a pension plan are offered. The low cost of living in Indianapolis makes salaries go further.
Development
Lilly invests heavily in employee development through Lilly University programs, external courses, and leadership development initiatives.
Mobility
Internal mobility between Indianapolis and coastal offices is supported with relocation assistance.
Publications
Publications are encouraged, and many Lilly scientists publish in top journals.
Growth
Lilly's stability and strong pipeline provide excellent long-term career prospects, further energized by the success of Mounjaro/Zepbound.
Culture
Career satisfaction is high given patient impact, scientific freedom, and work-life balance.
💊 Top Medicines & Blockbuster Drugs
Mounjaro/Zepbound (tirzepatide)
2022Indication: Type 2 diabetes (Mounjaro) and obesity (Zepbound)
Dual GIP/GLP-1 agonist - fastest ever drug launch
Annual Revenue (USD)
Trulicity (dulaglutide)
2014Indication: Type 2 diabetes - GLP-1 receptor agonist
Once-weekly injection - declining vs Mounjaro
Annual Revenue (USD)
Verzenio (abemaciclib)
2017Indication: Breast cancer - CDK4/6 inhibitor
HR+/HER2- breast cancer
Annual Revenue (USD)
Jardiance (empagliflozin)
2014Indication: Type 2 diabetes, heart failure, chronic kidney disease
SGLT2 inhibitor - cardiovascular benefits (BI partnership)
Annual Revenue (USD)
Taltz (ixekizumab)
2016Indication: Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis
IL-17A inhibitor
Annual Revenue (USD)